Latest News

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.
Vepdegestrant Meets PFS Primary End Point in ESR1m ER+/HER2– Breast Cancer

March 12th 2025

The safety profile of vepdegestrant in ER–positive/HER2– breast cancer was consistent with its observed profile in previous studies.

The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed
The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

March 11th 2025

Sexual Health Considerations to Improve Survivorship in Breast Cancer
Sexual Health Considerations to Improve Survivorship in Breast Cancer

March 11th 2025

The test led to a modification in treatment plan for 48.1% of those with stage I to III HER2-positive breast cancer, 73.5% of which were reductions.
Genomic Assay Yields Strong Predictive Accuracy in HER2+ Breast Cancer

March 11th 2025

Breast MRI in patients with newly diagnosed breast cancer increased mastectomy rates and biopsy needs.
Preoperative Breast MRI Does Not Improve Surgical Plan/Local Control

March 10th 2025

Video Series
Video Interviews
Podcasts
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.
Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.
Sarah Donahue, MPH, NP, speaks to the importance of communicating potential adverse effects associated with treatments such as CDK4/6 inhibitors to patients with breast cancer.
Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Early screening for breast cancer may help match patients with appropriate systemic therapies depending on the extent of their tumors, according to Rakhshanda Rahman, MD, FRCS, FACS.
Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
Rakhshanda Rahman, MD, FRCS, FACS, emphasizes educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

More News